Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 4, 2014, Pages 1090-1097

  Geretti, Anna Maria ^a   Conibear, Tim ^b   Hill, Andrew ^c   Johnson, Jeffrey A ^d   Tambuyzer, Lotke ^e   Thys, Kim ^e   Vingerhoets, Johan ^e   Van Delft, Yvon ^f   Rieger, A ^g   Vetter, N ^g   Greil, R ^g   Pedersen, C ^g   Storgaard, M ^g   Morlat, P ^g   Katlama, C ^g   Durant, J ^g   Cotte, L ^g   Duvivier, C ^g   Rey, D ^g   Esser, S ^g   Stellbrink, C ^g   Schmidt, W ^g   Stoll, M ^g   Stephan, C ^g   Fatkenheuer, G ^g   Stoehr, A ^g   Rockstroh, J ^g   Banhegyi, D ^g   Itzchak, L ^g   Shahar, E ^g   Maayan, S ^g   Turner, D ^g   Lazzarin, A ^g   Antinori, A ^g   Carosi, G ^g   Minoli, L ^g   Di Perri, G ^g   Filice, G ^g   Andreoni, M ^g   Duiculescu, D ^g   Rugina, S ^g   Erscoiu, S ^g   Streinu, A ^g   Pronin, A ^g   Pokrovsky, V ^g   Gruzdev, B ^g   Yakovlev, A ^g   Voronin, E ^g   Clotet, B ^g   Gatell, J ^g   Arribas, J ^g   Podzamczer, D ^g   Domingo, P ^g   Alvarez, C Miralles ^g   Quero, J Hernandez ^g   Furrer, H ^g   Feher, J ^g   Johnson, M ^g   Fox, J ^g   Nelson, M ^g   Fisher, M ^g   Orkin, C ^g   more..

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^c Janssen   (United Kingdom)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e JANSSEN RESEARCH FOUNDATION   (Belgium)

^f Janssen   (Netherlands)

^g NONE

Author keywords

ART; Genotyping; HIV

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; CELL DNA; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE PLUS ZIDOVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS DNA; VIRUS RNA;

ADULT; ALLELE; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DNA SEQUENCE; DRUG WITHDRAWAL; EUROPE; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; ISRAEL; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA; POLYMERASE CHAIN REACTION; RANDOMIZATION; RUSSIAN FEDERATION; SANGER SEQUENCING; SCORING SYSTEM; SINGLE DRUG DOSE; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; YOUNG ADULT;

ART; GENOTYPING; HIV;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; BENZOXAZINES; DNA, VIRAL; DRUG RESISTANCE; EUROPE; FEMALE; GENOTYPING TECHNIQUES; HIV INFECTIONS; HIV-1; HUMANS; ISRAEL; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PYRIDAZINES; RNA, VIRAL; RUSSIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896443660     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt474     Document Type: Article

References (42)

1. Gazzard B, Duvivier C, Zagler C et al. Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results. AIDS 2011; 25: 2249-58.
2. Nelson M, Stellbrink HJ, Podzamczer D et al. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. AIDS 2011; 25: 335-40.
3. Johnson JA, Geretti AM. Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution. J Antimicrob Chemother 2010; 65: 1322-6.
4. Johnson JA, Li JF, Wei X et al. Minority HIV-1 drug resistancemutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med 2008; 5: e158.
5. Geretti AM, Fox ZV, Booth CL et al. Low-frequency K103N strengthens the impact of transmitted drug resistance on virological responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 52: 569-73.
6. Simen BB, Simons JF, Hullsiek KH et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 2009; 199: 693-701.
7. Li JZ, Paredes R, Ribaudo HJ et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 2011; 305: 1327-35.
8. Li JZ, Paredes R, Ribaudo HJ et al. Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virological failure. J Infect Dis 2013; 207: 893-7.
9. Johnson JA, Li JF, Wei X et al. Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations. PLoS One 2007; 2: e638.
10. Asboe D, Aitken C, Boffito M et al. British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med 2012; 13: 1-44.
11. Pingen M, vander Ende ME, Wensing AM et al. Deep sequencing does not reveal additional transmitted mutations in patients diagnosed with HIV-1 variants with single nucleoside reverse transcriptase inhibitor resistance mutations. HIV Med 2013; 14: 176-81.
12. Gianella S, Delport W, Pacold ME et al. Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants. J Virol 2011; 85: 8359-67.
13. Quan Y, Brenner BG, Dascal A et al. Highly diversified multiply drug-resistant HIV-1 quasispecies in PBMCs: a case report. Retrovirology 2008; 5: 43.
14. Lee GQ, Swenson LC, Poon AF et al. Prolonged and substantial discordance in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC samples revealed by 454 "deep" sequencing. PLoS One 2012; 7: e46181.
15. Bon I, Gibellini D, Borderi M et al. Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients. J Clin Virol 2007; 38: 313-20.
16. Parisi SG, Boldrin C, Cruciani M et al. Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients. J Clin Microbiol 2007; 45: 1783-8.
17. Vicenti I, Razzolini F, Saladini F et al. Use of peripheral blood DNA for genotype antiretroviral resistance testing in drug-naive HIV-infected subjects. Clin Infect Dis 2007; 4b4: 1657-61.
18. Paolucci S, Baldanti F, Campanini G et al. Analysis of HIV drug-resistant quasispecies in plasma, peripheral bloodmononuclear cells and viral isolates from treatment-naive and HAART patients. J Med Virol 2001; 65: 207-17.
19. Ghosn J, Pellegrin I, Goujard C et al. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006; 20: 159-70.
20. Wang YM, Dyer WB, Workman C et al. Drug resistance and viral evolution in plasmaandperipheralbloodcellsduringstructuredtreatment interruption (STI) and non-interrupted HAART. Curr HIV Res 2007; 5: 235-50.
21. Bennett DE, Camacho RJ, Otelea D et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4: e4724.
22. Towner WJ, Cassetti I, Domingo P et al. Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance. Antivir Ther 2010; 15: 803-16.
23. Vingerhoets J, Tambuyzer L, Azijn H et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 2010; 24: 503-14.
24. Tambuyzer L, Nijs S, Daems B et al. Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virological response to etravirine. J Acquir Immune Defic Syndr 2011; 58: 18-22.
25. Messiaen P, Verhofstede C, Vandenbroucke I et al. Ultra-deep sequencing of HIV-1 reverse transcriptase before start of an NNRTI-based regimen in treatment-naive patients. Virology 2012; 426: 7-11.
26. Doyle T, Smith C, Vitiello P et al. Plasma HIV-1 RNA detection below 50 copies/mL and risk of virological rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2012; 54: 724-32.
27. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006; 42: 1608-18.
28. Booth CL, Geretti AM. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 2007; 59: 1047-56.
29. Vercauteren J, Wensing AM, van de Vijver DA et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009; 200: 1503-8.
30. Bartmeyer B, Kuecherer C, Houareau C et al. Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 seroconverter cohort. PLoS One 2010; 5: e12718.
31. Oette M, Reuter S, Kaiser R et al. Epidemiology of transmitted drug resistance in chronically HIV-infected patients in Germany: the RESINA study 2001-2009. Intervirology 2012; 55: 154-9.
32. Audelin AM, Gerstoft J, Obel N et al. Molecular phylogenetics of transmitted drug resistance in newly diagnosed HIV type 1 individuals in Denmark: a nation-wide study. AIDS Res Hum Retroviruses 2011; 27: 1283-90.
33. Karlsson A, Björkman P, Bratt G et al. Lowprevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010. PLoS One 2012; 7: e33484.
34. Dolling D, Sabin C, Delpech V et al. Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. British Med J 2012; 345: e5253.
35. Geretti AM, Fox Z, Johnson JA et al. Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. PLoS One 2013; 8: e69266.
36. Harrison L, Castro H, Cane P et al. The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. AIDS 2010; 24: 1917-22.
37. Wainberg MA, Moisi D, Oliveira M et al. Transmission dynamics of the M184V drug resistance mutation in primary HIV infection. J Antimicrob Chemother 2011; 66: 2346-9.
38. Readhead AC, Gordon DE, Wang Z et al. Transmitted antiretroviral drug resistance in New York State, 2006-2008: results from a new surveillance system. PLoS One 2012; 7: e40533.
39. Castor D, Low A, Evering T et al. Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York City. J Acquir Immune Defic Syndr 2012; 61: 1-8.
40. Yanik EL, Napravnik S, Hurt CB et al. Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients. J Acquir Immune Defic Syndr 2012; 61: 258-62.
41. Dudley DM, Chin EN, Bimber BN et al. Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance. PLoS One 2012; 7: e36494.
42. Ji H, Liang B, Li Y et al. Low abundance drug resistance variants in transmitted HIV drug resistance surveillance specimens identified using tagged pooled pyrosequencing. J Virol Methods 2013; 187: 314-20.